Nutanix stands out as a resilient AI infrastructure play amid tech sector volatility and SaaS weakness. Click here to read an analysis of NTNX stock here.
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results